

### Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

November 8, 2022

- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 -
  - Strong cash balance of \$179.9 million supports all planned operations into Q2 2025 -

LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing Al-powered precision T cell therapies to treat solid tumors, today announced its financial results for the third quarter ended September 30, 2022, and recent business highlights.

"This quarter we continued to advance our clinical programs and look forward to providing an update from our ongoing Phase I/Ila CHIRON and THETIS clinical trials in non-small cell lung cancer (NSCLC) and melanoma, respectively, at the ESMO Immuno-Oncology Annual Congress," said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics. "A poster entitled 'Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells,' will be presented and available from December 6, 2022. We expect additional clinical data readouts across our programs throughout 2023 which, along with our strong cash balance, position Achilles well for the future."

#### **Financial Highlights**

- Cash and cash equivalents: Cash and cash equivalents were \$179.9 million as of September 30, 2022, as compared to \$266.3 million as of December 31, 2021. The impact of translating our books and records from British Pounds Sterling into U.S. dollars had an unfavorable impact on the reported balance cash and cash equivalents. The net decrease reflects an underlying use of \$45.7 million for operating and investing activities and a negative \$40.7 million foreign exchange impact. The Company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the second quarter of 2025, including completion of the ongoing Phase I/IIa CHIRON and THETIS clinical trials.
- Research and development (R&D) expenses: R&D expenses were \$10.6 million for the third quarter ended September 30, 2022, as compared to \$10.7 million for the third quarter ended September 30, 2021.
- General and administrative (G&A) expenses: G&A expenses were \$5.4 million for the third quarter ended September 30, 2022, as compared to \$5.0 million for the third quarter ended September 30, 2021. The increase was primarily driven by an increase in personnel costs.
- **Net loss:** Net loss for the third quarter ended September 30, 2022, was \$12.5 million or \$0.32 per share compared to \$12.9 million, or \$0.34 per share for the third quarter ended September 30, 2021.

#### **Upcoming Events**

Achilles will participate in the following investor and medical conferences. Additional details will be available in the Events & Presentations section of the Company's website:

- Jefferies London Healthcare Conference: November 15 17, 2022
- TIDES Europe Oligonucleotide & Peptide Therapeutics: November 16 18, 2022
- Piper Sandler Annual Healthcare Conference: November 29 December 1, 2022
- ESMO Immuno-Oncology Congress 2022: December 7 − 9, 2022
- J.P. Morgan Annual Healthcare Conference: January 9 12, 2023

#### **About Achilles Therapeutics**

Achilles is a clinical-stage biopharmaceutical company developing Al-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develops precision T cell-based product candidates specifically targeting those clonal neoantigens.

#### **Forward-Looking Statements**

This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results,

performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

#### Investors:

Achilles Therapeutics Lee M. Stern, VP, IR & External Communications Lstern@achillestx.com

LifeSci Advisors John Mullaly imullaly@lifesciadvisors.com

#### Media:

Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000
achillestx@consilium-comms.com

## ACHILLES THERAPEUTICS PLC Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except share and per share amounts) (expressed in U.S. Dollars, unless otherwise stated)

Sure of the equivalents         179,890         266,319           Cash and cash equivalents         18,797         18,430           Total current assets         18,797         284,749           Non-current assets         17,419         17,749           Prepatiq and equipment, net         17,419         17,743           Operating lease right of use assets         26         26           Restricted cash         23         3           Other assets         2,713         3.50           Total one-current assets         2,750         3.50           Total one-current assets         2,750         3.70           Total ASSETS         5,751         5         3.72           Accurred expenses and other liabilities         7,745         9         3.72           Income taxes payable         7,465         9         7.57         9         4.482         7.77         10         4.482         7.77         10         6         4.482		Sep	otember 30, 2022	December 31, 2021		
Cash and cash equivalents         \$ 179,890         \$ 266,319           Prepaid expenses and other current assets         19,670         18,400           Non-current assets         196,677         284,740           Property and equipment, net         17,741         17,743           Operating lease right of use assets         8,472         11,048           Deferred tax assets         8,472         11,048           Deferred tax assets         2,733         3,03           Other assets         2,713         3,507           Total onn-current assets         2,273.00         3,307           Total non-current assets         2,273.00         3,307           Total non-current assets         2,273.00         3,307           Total current liabilities         2,273.00         3,307           Total pon-current liabilities         5         27,707           Accounts payable         5         7,516         9         3,722           Income taxes payable         7,456         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906	ASSETS					
Prepaid expenses and other current assets         18,807         18,404           Total current assets         198,687         284,749           Non-current assets:         700         17,419         17,743           Operating lease right of use assets         8,472         110,48           Deferred tax assets         26         26           Restricted cash         33         3,30           Other assets         2,713         3,507           Total non-current assets         2,733         35,70           TOTAL ASSETS         2,2735         317,106           Current liabilities           Current liabilities           Accounts payable         7,516         3,722           Accured expenses and other liabilities         7,45         10,906           Operating lease liabilities-current         4,036         4,482           Official gase liabilities-current         4,952         7,777           Other long-term liabilities         4,952         7,777           Other long-term liabilities         5,678         6,91           Total connective ribilities         24,73         2,75           Ordinary shares, £0,001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 a	Current assets:					
Total current assets         198.687         284,749           Non-current assets         77,479         17,749         17,749           Property and equipment, net         17,419         17,749         110,408           Operating lease right of use assets         8,472         111,048         26         26           Restricted cash         33         33         33         33         35         35,07         30	Cash and cash equivalents	\$	179,890	\$	266,319	
Non-current assets:         70perty and equipment, net         17,419         17,419         17,419         17,419         17,419         17,419         17,419         17,418         17,418         10,418         26         27         27         26         26         27         27         26         26         27         27         26         26         27         27         27         26         26         27         27         27         27         27	Prepaid expenses and other current assets		18,797		18,430	
Property and equipment, net         17,419         17,7419           Operating lease right of use assets         8,472         11,048           Deferred tax assets         26         26           Restricted cash         33         33           Other assets         2,713         3,507           Total non-current assets         22,7350         \$37,106           TOTAL ASSETS         222,7350         \$37,106           LIABILITIES AND SHAREHOLDERS' EQUITY           Current liabilities           Accounts payable         5,516         \$3,722           Income taxes payable         59         -           Accured expenses and other liabilities         19,056         19,106           Operating lease liabilities-current         4,036         4,482           Total current liabilities         19,056         19,110           Non-current liabilities         7,777         10 (100)         19,056         19,110           Operating lease liabilities-non-current         4,952         7,777           Other long-term liability         726         691           Total current liabilities         5,678         8,486           Total liabilities         5,678         8,486	Total current assets		198,687		284,749	
Operating lease right of use assets         8,472         11,048           Deferred tax assets         26         26           Restricted cash         33         33           Other assets         2,713         3,507           Total non-current assets         28,663         32,357           TOTAL ASSETS         \$ 227,350         \$ 317,106           LIABILITIES AND SHAREHOLDERS' EQUITY           Current liabilities           Current liabilities         59         —           Accounts payable         59         —           Accrued expenses and other liabilities         59         —           Accrued expenses and other liabilities         4,962         19,056           Operating lease liabilities-current         4,952         7,777           Other long-term liabilities         4,952         7,777           Other long-term liabilities         7,45         691           Operating lease liabilities-non-current         4,952         7,777           Other long-term liabilities         2,77         691           Operating lease liabilities         2,72         691           Total non-current liabilities         2,72         691           Total liabilities         5,678	Non-current assets:				_	
Deferred tax assets         26         28           Restricted cash         33         33           Other assets         2,713         3,507           Total non-current assets         28,663         32,357           TOTAL ASSETS         2027,350         317,006           LIABILITIES AND SHAREHOLDERS' EQUITY           Current liabilities           Accounts payable         59         -           Accorust payable         59         -           Accurued expenses and other liabilities         7,445         10,906           Operating lease liabilities-current         19,056         19,110           Non-current liabilities         19,056         7,777           Other long-term liabilities         4,952         7,777           Operating lease liabilities-non-current         4,952         7,777           Other long-term liabilities         24,30         24,73           Total non-current liabilities         24,73         3,68           Total liabilities         24,73         3,752           Operating lease liabilities, non-current liability         5,678         8,488           Total non-current liabilities         24,73         3,757           Operating lease liabilities, non-c	Property and equipment, net		17,419		17,743	
Restricted cash         33         3.507           Other assets         2,713         3.507           Total non-current assets         28,663         32,357           TOTAL ASSETS         28,063         317,106           LIABILITIES AND SHAREHOLDERS' EQUITY           Current liabilities:           Accounts payable         7,516         3,722           Accounts payable         59         -           Accurred expenses and other liabilities         59         -           Operating lease liabilities-current         4,952         7,777           Operating lease liabilities-current         19,056         19,110           Non-current liabilities         19,056         9,110           Von-current liabilities         7,277         19,056         9,177           Other long-term liabilities         7,266         691           Total non-current liabilities         2,473         27,578           Ordinal polities         2,473         27,578           Commitments and contingencies (Note 12)         3,678         8,488           Total liabilities         2,473         2,578           Commitments and contingencies (Note 12)         5         5           Shareholders' equity:<	Operating lease right of use assets		8,472		11,048	
Other assets         2,713         3,507           Total non-current assets         28,663         32,357           TOTAL ASSETS         \$227,350         \$317,106           LIABILITIES AND SHAREHOLDERS' EQUITY           Current liabilities:           Accounts payable         \$7,516         \$3,722           Income taxes payable         59         —           Accrude expenses and other liabilities         7,445         10,906           Operating lease liabilities-current         4,036         4,482           Total current liabilities         19,056         19,110           Non-current liabilities         4,952         7,777           Other long-term liabilities in current liabilities         726         691           Total non-current liabilities         5,678         8,488           Total liabilities         24,734         27,578           Commitments and contingencies (Note 12)         5,678         8,488           Total liabilities         24,734         27,578           Commitments and contingencies (Note 12)         5         5           Shareholders' equity:         54         54           Ordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 and Dec	Deferred tax assets		26		26	
Total non-current assets         28.663         32,357           TOTAL ASSETS         227,350         317,106           LABILITIES AND SHAREHOLDERS' EQUITY           Current liabilities           Accounts payable         \$ 7,516         \$ 3,722           Income taxes payable         59         —           Accrued expenses and other liabilities         7,445         10,906           Operating lease liabilities-current         4,036         4,482           Total current liabilities         19,056         19,110           Non-current liabilities         4,952         7,777           Other long-term liability         726         691           Total non-current liabilities         5,678         8,488           Total liabilities         24,734         27,578           Ormitments and contingencies (Note 12)         5,678         8,488           Shareholders' equity:         5         5         8           Ordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively         54         54         54           Deferred shares, £92,451,851 par value, one share authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively         128         128<	Restricted cash		33		33	
TOTAL ASSETS   \$ 227,350   \$ 317,106	Other assets		2,713		3,507	
LIABILITIES AND SHAREHOLDERS' EQUITY           Current liabilities:         \$ 7,516         \$ 3,722           Accounts payable         59         —           Accrued expenses and other liabilities         7,445         10,906           Operating lease liabilities-current         4,036         4,882           Total current liabilities         19,056         19,110           Non-current liabilities:         19,056         19,110           Operating lease liabilities-non-current         4,952         7,777           Other long-term liability         726         691           Total non-current liabilities         5,678         8,468           Total liabilities         24,734         27,578           Commitments and contingencies (Note 12)         Shareholders' equity:         54         54           Ordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively         54         54           Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively         128         128           Additional paid in capital         407,155         401,821           Accumulated other comprehensive (loss) income         (38,490)         6,636	Total non-current assets		28,663		32,357	
Current liabilities:         X,516         \$ 3,722           Accounts payable         59         —           Accrued expenses and other liabilities         7,445         10,906           Operating lease liabilities-current         4,036         4,482           Total current liabilities:         19,056         19,110           Non-current liabilities:         20         7,777           Other long-term liabilities -non-current         4,952         7,777           Other long-term liabilities         726         691           Total non-current liabilities         5,678         8,468           Total liabilities         24,734         27,578           Commitments and contingencies (Note 12)         5,678         8,468           Shareholders' equity:         24,734         27,578           Cordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively         54         54           Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively         128         128           Additional paid in capital         407,155         401,821           Accumulated other comprehensive (loss) income         (38,490)         6,636           <	TOTAL ASSETS	\$	227,350	\$	317,106	
Accounts payable         \$ 7,516         \$ 3,722           Income taxes payable         59         —           Accrued expenses and other liabilities         7,445         10,906           Operating lease liabilities-current         4,036         4,482           Total current liabilities         19,056         19,110           Non-current liabilities         2         7,777           Operating lease liabilities-non-current         4,952         7,777           Other long-term liability         726         691           Total non-current liabilities         5,678         8,468           Total liabilities         24,734         27,578           Commitments and contingencies (Note 12)         5         24,734         27,578           Commitments and contingencies (Note 12)         5         54         54           Ordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively         54         54           Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at September 30, 2022 and December 31, 2021         128         128           Additional paid in capital         407,155         401,821           Accumulated other comprehensive (loss) income         (38,490)         6,636 <td>LIABILITIES AND SHAREHOLDERS' EQUITY</td> <td></td> <td></td> <td></td> <td></td>	LIABILITIES AND SHAREHOLDERS' EQUITY					
Income taxes payable         59         —           Accrued expenses and other liabilities         7,445         10,906           Operating lease liabilities-current         4,036         4,482           Total current liabilities         19,056         19,110           Non-current liabilities:         ************************************	Current liabilities:					
Income taxes payable         59         —           Accrued expenses and other liabilities         7,445         10,906           Operating lease liabilities-current         4,036         4,482           Total current liabilities         19,056         19,110           Non-current liabilities:         ************************************	Accounts payable	\$	7,516	\$	3,722	
Operating lease liabilities-current         4,036         4,482           Total current liabilities         19,056         19,110           Non-current liabilities:         20         7,777           Other long-term liability         726         691           Total non-current liabilities         5,678         8,468           Total liabilities         24,734         27,578           Commitments and contingencies (Note 12)         Shareholders' equity:         5           Ordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively         54         54           Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at September 30, 2022 and December 31, 2021         128         128           Additional paid in capital         407,155         401,821           Accumulated other comprehensive (loss) income         (38,490)         6,636           Accumulated deficit         (166,231)         (119,111)			59		_	
Total current liabilities         19,056         19,110           Non-current liabilities:         2         7,777           Other long-term liability         726         691           Total non-current liabilities         5,678         8,468           Total liabilities         24,734         27,578           Commitments and contingencies (Note 12)         Shareholders' equity:         Variable of the control of the	Accrued expenses and other liabilities		7,445		10,906	
Non-current liabilities:  Operating lease liabilities-non-current Other long-term liability Total non-current liabilities Total non-current liabilities Total liabilities Total liabilities Total non-current liabilities Total liabilities Total non-current liabilities Total liabilities Total non-current liabilities Total non-current liabilities Total liabilities Total non-current liabilitie	Operating lease liabilities-current		4,036		4,482	
Operating lease liabilities-non-current         4,952         7,777           Other long-term liability         726         691           Total non-current liabilities         5,678         8,468           Total liabilities         24,734         27,578           Commitments and contingencies (Note 12)         Shareholders' equity:         5           Ordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively         54         54           Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at September 30, 2022 and December 31, 2021         128         128           Additional paid in capital         407,155         401,821           Accumulated other comprehensive (loss) income         (38,490)         6,636           Accumulated deficit         (196,231)         (119,111)	Total current liabilities		19,056		19,110	
Other long-term liability         726         691           Total non-current liabilities         5,678         8,468           Total liabilities         24,734         27,578           Commitments and contingencies (Note 12)         Shareholders' equity:         Ordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively         54         54           Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at September 30, 2022 and December 31, 2021         128         128           Additional paid in capital         407,155         401,821           Accumulated other comprehensive (loss) income         (38,490)         6,636           Accumulated deficit         (166,231)         (119,111)	Non-current liabilities:					
Total non-current liabilities 5,678 24,734 27,578  Total liabilities 24,734 27,578  Commitments and contingencies (Note 12)  Shareholders' equity:  Ordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively 54 54  Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at September 30, 2022 and December 31, 2021 and December 31,	Operating lease liabilities-non-current		4,952		7,777	
Total liabilities 24,734 27,578  Commitments and contingencies (Note 12)  Shareholders' equity:  Ordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively 54 54  Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at September 30, 2022 and December 31, 2021 128 128  Additional paid in capital 407,155 401,821  Accumulated other comprehensive (loss) income (38,490) 6,636  Accumulated deficit (166,231) (119,111)	Other long-term liability		726		691	
Commitments and contingencies (Note 12) Shareholders' equity:  Ordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively  Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at September 30, 2022 and December 31, 2021  Additional paid in capital  Accumulated other comprehensive (loss) income  (38,490)  6,636  Accumulated deficit  (166,231)	Total non-current liabilities		5,678		8,468	
Shareholders' equity:  Ordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively  Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at September 30, 2022 and December 31, 2021  Additional paid in capital  Accumulated other comprehensive (loss) income  (38,490)  6,636  Accumulated deficit  (166,231)  (119,111)	Total liabilities		24,734		27,578	
Ordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively  Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at September 30, 2022 and December 31, 2021  Additional paid in capital  Accumulated other comprehensive (loss) income  Accumulated deficit  Ordinary shares, £0.001 par value; 40,938,763 and 40,603,489 shares authorized, issued and outstanding at 128  128  128  407,155  401,821  Accumulated deficit  (166,231)  (119,111)	Commitments and contingencies (Note 12)					
outstanding at September 30, 2022 and December 31, 2021, respectively  Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at September 30, 2022 and December 31, 2021  Additional paid in capital  Accumulated other comprehensive (loss) income  Accumulated deficit  54  407,155  401,821  407,155  401,821  407,155  401,821  407,155  401,821  407,155  401,821  407,155  401,821  407,155  401,821	Shareholders' equity:					
September 30, 2022 and December 31, 2021       128       128         Additional paid in capital       407,155       401,821         Accumulated other comprehensive (loss) income       (38,490)       6,636         Accumulated deficit       (166,231)       (119,111)			54		54	
Additional paid in capital       407,155       401,821         Accumulated other comprehensive (loss) income       (38,490)       6,636         Accumulated deficit       (166,231)       (119,111)	Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at					
Accumulated other comprehensive (loss) income         (38,490)         6,636           Accumulated deficit         (166,231)         (119,111)	September 30, 2022 and December 31, 2021		128		128	
Accumulated deficit (166,231) (119,111)	Additional paid in capital		407,155		401,821	
	Accumulated other comprehensive (loss) income		(38,490)		6,636	
Total shareholders' equity 202,616 289,528	Accumulated deficit		(166,231)		(119,111)	
	Total shareholders' equity		202,616		289,528	

227,350

# ACHILLES THERAPEUTICS PLC Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share amounts)

	Three Months Ended September 30,			Nine Months Ended September 30,				
		2022	2021		2022		2021	
OPERATING EXPENSES:								
Research and development	\$	10,597	\$	10,697	\$	38,387	\$	30,417
General and administrative		5,437		5,041		17,162		15,318
Total operating expenses		16,034		15,738		55,549		45,735
Loss from operations		(16,034)		(15,738)		(55,549)		(45,735)
OTHER INCOME, NET:								
Other income		3,599		2,806		8,499		2,907
Total other income, net		3,599		2,806		8,499		2,907
Loss before provision for income taxes		(12,435)		(12,932)		(47,050)		(42,828)
Provision for income taxes		(41)		(16)		(70)		(41)
Net loss		(12,476)		(12,948)		(47,120)		(42,869)
Other comprehensive income:				_		_		
Foreign exchange translation adjustment		(18,147)		(7,710)		(45,126)		(6,572)
Comprehensive loss	\$	(30,623)	\$	(20,658)	\$	(92,246)	\$	(49,441)
Net loss per share attributable to ordinary shareholders—basic and diluted	\$	(0.32)	\$	(0.34)	\$	(1.20)	\$	(1.69)
Weighted average ordinary shares outstanding—basic and diluted		39,313,764	_	38,261,480	_	39,104,866		25,329,672